FDA & Government News

After Roe, the Numbers Tell a Surprise

Share

The 53rd anniversary of Roe v. Wade marks a significant turning point since the Supreme Court's overturning of the decision, leading to bans in 13 states and restrictions in 10 others. Despite legal limitations, abortion rates persist, largely facilitated by increased access to medication abortion via telehealth. Mifepristone's approval and its availability through mail have enhanced its use, with over 60% of abortions performed medically by 2023. Abortion opponents express frustration over continued access and the FDA's regulatory pace, reflecting ongoing tensions in reproductive health policies.

Original Source(s)

Related Content